Detalhe da pesquisa
1.
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
PLoS One;
14(9): e0222650, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31560700
2.
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Infect Dis (Lond);
50(5): 352-360, 2018 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29210336
3.
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
AIDS;
19(3): 287-94, 2005 Feb 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15718839
4.
Pandemic (H1N1) 2009 and HIV co-infection.
Emerg Infect Dis;
16(10): 1643-4, 2010 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20875304
5.
Nonnucleoside reverse transcriptase inhibitor-containing regimens are associated with increased satisfaction with sexual life.
J Acquir Immune Defic Syndr;
34(5): 532-4, 2003 Dec 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14657766